Journal profile · Hematology
Journal of Hematology & Oncology
ISSN 1756-8722 · BioMed Central · ENGLAND · Irregular · Founded 2008
Journal of Hematology & Oncology: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 47.75; fully open access; APC about USD 5,190; median 80 days to acceptance (87 articles, last 24 months); 118 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Journal of Hematology & Oncology is published by BioMed Central and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are CAR-T cell therapy research, Acute Myeloid Leukemia Research and Lymphoma Diagnosis and Treatment, together about 26.5% of its articles. Its main subfields are Hematology. (generated from OpenAlex topic counts and CAS ranking data)
Journal of Hematology & Oncology is an open access journal that publishes top-quality research encompassing all aspects of hematology and oncology. The journal also publishes reviews and research highlights on "hot topics" from leading experts in the field. Hematology and oncology are closely intertwined and rapidly evolving fields. More physician scientists performing laboratory-based research are rapidly bringing research in hematology and oncology from bench to bedside. Journal of Hematology & Oncology aims to meet the demand for a journal dedicated to publishing discovery from both of these fields. Journal of Hematology & Oncology aims to serve as an international platform for sharing laboratory and clinical findings in an open access format among laboratory scientists, physician scientists, hematologists and oncologists. A rapid turnaround time from submission to publication means that knowledge and new successes can be shared in real time.
From the journal's Aims & Scope
Research area (LetPub): Hematology
Editor-in-chief Delong LiuPublisher website
Editorial board by country: 16 in mainland China (about 30%); most named United States 25, Mainland China 16, France 2, Italy 2, Spain 2 (54 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- CAR-T cell therapy researchMedicine10%
- Acute Myeloid Leukemia ResearchMedicine9.7%
- Lymphoma Diagnosis and TreatmentMedicine6.7%
- Cancer Immunotherapy and BiomarkersMedicine5.8%
- Immune Cell Function and InteractionImmunology and Microbiology4.9%
- Multiple Myeloma Research and TreatmentsMedicine4.7%
- Acute Lymphoblastic Leukemia researchMedicine4.7%
- Immunotherapy and Immune ResponsesImmunology and Microbiology4.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Hematology | Zone 1 |
| Minor | Oncology | Zone 1 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 1 |
| Minor | Hematology | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Hematology | Zone 1 |
| Minor | Oncology | Zone 1 |
Top journal: yesReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEEmbaseCASPublisher website
Other: Google Scholar, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS, Semantic Scholar
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 47.75LetPub ·
- Impact factor (publisher) 2025
- 47.8Publisher website ·
- 5-year impact factor (publisher) 2025
- 42.7Publisher website ·
- CiteScore 2026-06
- 70.1LetPub ·
- SJR 2026-06
- 11.82LetPub ·
- SNIP 2026-06
- 7.62LetPub ·
- h-index
- 60LetPub ·
- h-index
- 235OpenAlex ·
- i10-index
- 1,895OpenAlex ·
- 2-year mean citedness
- 35.16OpenAlex ·
- Self-citation rate
- 1%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 75LetPub ·
- Downloads per year (publisher) 2025
- 4,600,000Publisher website ·
Articles by year OpenAlex count · 2,203 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 74 | 74 | 148 |
| 2025 | 118 | 118 | 3,543 |
| 2024 | 132 | 132 | 7,701 |
| 2023 | 123 | 123 | 10,122 |
| 2022 | 178 | 178 | 22,516 |
| 2021 | 206 | 206 | 27,358 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
80 daysMedian, submission to acceptance · P25–P75 65 days – 107 days
- Acceptance to online
- median 19 days (87 articles)
- Submission to online
- median 109 days
- Sample
- 87 articles with submission and acceptance dates (238 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Submission to first decision
- 8 daysPublisher website ·
- Submission to publication (journal-reported)
- about 6 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 4,490 / USD 5,190 / GBP 3,690 | Yes | CC BY, CC BY-NC-ND | |
| OpenAlex | USD 4,990 / EUR 4,290 / GBP 3,590 | — | — | |
| LetPub | GBP 3,390 / USD 4,690 / EUR 3,990 | Yes | — | |
| Publisher website | GBP 3,690 / USD 5,190 / EUR 4,490 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare4 items from the author guidelines
- Reference style
- Numbered, in order of citation
- Templates
- LaTeX
- Suggested reviewers
- Optional
- Not considered
- requests made during the review process or after acceptance
Article types accepted5
- case reportFormatting guidelines for specific article types can be found below. Research Review Correspondence Research highlight Case reportLength not stated
- correspondenceFormatting guidelines for specific article types can be found below. Research Review Correspondence Research highlight Case reportLength not stated
- researchFormatting guidelines for specific article types can be found below. Research Review Correspondence Research highlight Case reportLength not stated
- research highlightFormatting guidelines for specific article types can be found below. Research Review Correspondence Research highlight Case reportLength not stated
- reviewFormatting guidelines for specific article types can be found below. Research Review Correspondence Research highlight Case reportLength not stated
Policy excerpts from the journal's websiteData availability, License & copyright, Open access, Peer review
- Data availability Formatting the 'Availability of data and materials' section of your manuscript
The following format for the 'Availability of data and materials section of your manuscript should be used:
Source ↗Publisher website ·- License & copyright Licensing and copyright
Creative Commons licences Open access articles in Springer Nature journals are published under Creative Commons licences. These provide an industry-standard framework to support easy re-use of open access material. Under Creative Commons licences, authors retain copyright of their articles. Journal of Hematology & Oncology articles are published open access under a CC BY-NC-ND (Creative Commons At…
Source ↗Publisher website ·- Open access Benefits of open access
Publishing open access (OA) offers a number of benefits, including greater reach and readership for your work: Cited more 1.6x more citations of OA articles than non-OA articles across all subjects Downloaded more 4x more downloads of OA articles than non-OA articles Greater impact 2.5x more Altmetric attention. OA articles attracted 1.9x more news mentions and 1.2x more policy mentions Open acces…
Source ↗Publisher website ·- Peer review Peer review policy
Peer review is the process used to evaluate the quality of a manuscript before publication. Independent researchers in the relevant field assess submitted manuscripts to check their validity and robustness. Their feedback guides editors in making publication decisions. Typically, two or more experts evaluate each manuscript based on three main criteria: scientific robustness: is the research metho…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- BioMed Central
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Irregular
- Founded
- 2008
- ISSN
- 1756-8722
- Society / sponsor
- Chinese American Hematologist and Oncologist Network
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Journal of Hematology & Oncology
What CAS zone is Journal of Hematology & Oncology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Journal of Hematology & Oncology is in Zone 1 of Medicine, and in Zone 1 of the minor category Hematology / Oncology; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Journal of Hematology & Oncology?
The latest impact factor listed by LetPub is 47.75; CiteScore 70.1, h-index 235.
How long does peer review take at Journal of Hematology & Oncology?
Based on the dates recorded on 87 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 80 days (interquartile range 65–107 days); authors report an average review time of 6–12 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Journal of Hematology & Oncology?
According to the journal's author guidelines: Reference style: Numbered, in order of citation; Templates: LaTeX; Suggested reviewers: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Journal of Hematology & Oncology based?
Of the 54 board members whose country the journal's board page names, 16 (about 30%) are in mainland China; the countries named most often are United States (25), Mainland China (16) and France (2). Counted from the institutions listed on the board page; for reference only.
Which databases index Journal of Hematology & Oncology?
According to LetPub and DOAJ records, Journal of Hematology & Oncology is indexed in SCIE, Scopus and DOAJ. The journal's website also lists MEDLINE, Embase and CAS; that list has not been checked against each database.
Is Journal of Hematology & Oncology open access, and what is the APC?
Journal of Hematology & Oncology is a fully open-access journal. APC about USD 5,190.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .